Post by
canyousayiii on Feb 01, 2021 12:36pm
Jan 27 - continued "buy"
2021-01-27 08:19 ET - In the News The Globe and Mail reports in its Wednesday, Jan. 27, edition that Canaccord Genuity analyst Robert Young continues to rate Docebo "buy." The Globe's David Leeder writes in the Eye On Equities column that Mr. Young boosted his share target by $2 to $72, matching the consensus (all figures U.S.). Mr. Young says in a note: "Docebo provided a preliminary view of Q4/20 results alongside a marketed $100-million secondary public offering. [Annual recurring revenue] continues to trend ahead of expectations. Q4 ARR is expected to be $73-million to $74-million, up 55-57 per cent year-over-year exiting December, versus our $70.6-million estimate. This is the sixth straight quarter of 50-per-cent-plus ARR growth and an extension of recent growth acceleration from 54.5-per-cent ARR growth in Q2 and 54.9-per-cent growth in Q3. Given a lack of large deal announcements, the quarter appears to be driven by singles and doubles, which underscores the momentum in the business, in our view. We remain positive and confident in the company's growth outlook." The Globe reported on Dec. 10 that Laurentian Bank Securities analyst Nick Agostino began coverage of Docebo with a "buy." The shares could then be had for $48.80.
Comment by
LowtoHigh on Feb 01, 2021 8:21pm
Yes. I own and confident it will reach the 72 usd target. It has been climbing since recent news of new issue. That is a great sign!
Comment by
jjj123 on Feb 03, 2021 4:45am
Doubled down my postion last few days at $62 and $64. Now holding 300 shares at avg of $52. Expect to be quite happy through this year. GLTA.
Comment by
LowtoHigh on Feb 03, 2021 5:59pm
Nice! I unfortunately got it higher before the NR on new issues. But still holding and agree it will rise.